EUCTR2012-003073-26-BE进行中（未招募）1 期
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 478
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.The subject has received at least one dose of ABT-450, ABT-333 or ABT-267 in a prior AbbVie HCV Phase 2 or 3 study
- •2.The interval between the last dose of the AbbVie DAA therapy from the previous clinical study and enrollment in Study M13-102 must be no longer than 2 years.
- •3.The subject must voluntarily sign and date the informed consent form approved by an Independent Review Board or Ethics Committee prior to the initiation of any study-specific procedures.
- •4. Subject completed the post-treatment period of an eligible prior study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 450
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. The investigator considers the subject unsuitable for the study for any reasons (e.g., failure to comply with study procedures in the prior AbbVie clinical study).
- •2. Receipt of any investigational product from Day 1 and while enrolled in this study
研究者
相似试验
进行中（未招募）
1 期
A follow up study designed to obtain long term data on subjects who either achieved a sustained virologic response or or did not achieve a sustained virologic response in an AbbVie sponsored hepatitis C studyMedDRA version: 18.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsHepatitis CEUCTR2012-003073-26-DEAbbVie Deutschland GmbH & Co. KG500
进行中（未招募）
1 期
A follow up study designed to obtain long term data on subjects who either achieved a sustained virologic response or or did not achieve a sustained virologic response in an AbbVie sponsored hepatitis C studyMedDRA version: 16.1 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsHepatitis CEUCTR2012-003073-26-ITAbbVie Deutschland GmbH & Co. KG478
进行中（未招募）
1 期
A follow up study designed to obtain long term data on subjects who either achieved a sustained virologic response or or did not achieve a sustained virologic response in an AbbVie sponsored hepatitis C studyHepatitis CEUCTR2012-003073-26-DKAbbVie Deutschland GmbH & Co. KG500
进行中（未招募）
1 期
A follow up study designed to obtain long term data on subjects who either achieved a sustained virologic response or or did not achieve a sustained virologic response in an AbbVie sponsored hepatitis C studyMedDRA version: 16.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsHepatitis CEUCTR2012-003073-26-PTAbbVie Deutschland GmbH & Co. KG500
进行中（未招募）
1 期
A follow up study designed to obtain long term data on subjects who either achieved a sustained virologic response or or did not achieve a sustained virologic response in an AbbVie sponsored hepatitis C studyHepatitis CEUCTR2012-003073-26-GBAbbVie Deutschland GmbH & Co. KG478